These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 1826738)

  • 1. Will it play in Peoria?
    Grunberg SM
    J Clin Oncol; 1991 May; 9(5):713-5. PubMed ID: 1826738
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
    Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
    J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
    Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
    J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.
    Marty M; Pouillart P; Scholl S; Droz JP; Azab M; Brion N; Pujade-Lauraine E; Paule B; Paes D; Bons J
    N Engl J Med; 1990 Mar; 322(12):816-21. PubMed ID: 2137902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review.
    Marschner N
    Eur J Cancer; 1991; 27 Suppl 1():S15-7; discussion S22. PubMed ID: 1831629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
    Kris MG; Tyson LB; Clark RA; Gralla RJ
    Cancer; 1992 Aug; 70(4 Suppl):1012-6. PubMed ID: 1386282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo.
    Gandara DR; Harvey WH; Monaghan GG; Perez EA; Stokes C; Bryson JC; Finn AL; Hesketh PJ
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):67-71. PubMed ID: 1387253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical studies with ondansetron in the control of radiation-induced emesis.
    Priestman TJ
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S29-33. PubMed ID: 2533896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting.
    Marty M
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S41-5. PubMed ID: 2533898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ondansetron versus metoclopramide in prophylaxis of nausea and vomiting for laparoscopic cholecystectomy: a prospective double-blind randomized study.
    Sandhu T; Tanvatcharaphan P; Cheunjongkolkul V
    Asian J Surg; 2008 Apr; 31(2):50-4. PubMed ID: 18490214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parenteral ondansetron for the treatment of chemotherapy- and radiation-induced nausea and vomiting.
    Burnette PK; Perkins J
    Pharmacotherapy; 1992; 12(2):120-31. PubMed ID: 1533280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ondansetron vs. metoclopramide for the prevention of nausea and vomiting after gynecologic surgery.
    Krobbuaban B; Pitakpol S; Diregpoke S
    J Med Assoc Thai; 2008 May; 91(5):669-74. PubMed ID: 18672630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes.
    Schmoll HJ
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S35-9. PubMed ID: 2533897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effectiveness of rescue antiemetics after failure of prophylaxis with ondansetron or droperidol: a preliminary report.
    Habib AS; Gan TJ
    J Clin Anesth; 2005 Feb; 17(1):62-5. PubMed ID: 15721732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylaxis of postoperative nausea and vomiting with ondansetron, metoclopramide, or placebo in total intravenous anesthesia patients undergoing laparoscopic cholecystectomy.
    Kaki AM; Abd El-Hakeem EE
    Saudi Med J; 2008 Oct; 29(10):1408-13. PubMed ID: 18946563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis.
    Bhatia A; Tripathi KD; Sharma M
    Indian J Med Res; 2004 Sep; 120(3):183-93. PubMed ID: 15489556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo.
    Egerton-Warburton D; Meek R; Mee MJ; Braitberg G
    Ann Emerg Med; 2014 Nov; 64(5):526-532.e1. PubMed ID: 24818542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metoclopramide versus ondansetron for the treatment of vomiting in children with acute gastroenteritis.
    Al-Ansari K; Alomary S; Abdulateef H; Alshawagfa M; Kamal K
    J Pediatr Gastroenterol Nutr; 2011 Aug; 53(2):156-60. PubMed ID: 21788756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of ondansetron in oncology].
    Laplanche A; Gérondeau N
    Bull Cancer; 1993 Jul; 80(7):568-76. PubMed ID: 8204937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of chemotherapy-related nausea and vomiting using a serotonin antagonist.
    Egan AP; Taggart JR; Bender CM
    Oncol Nurs Forum; 1992 Jun; 19(5):791-5. PubMed ID: 1535124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.